These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 36115181)

  • 21. S100A14 promotes progression and gemcitabine resistance in pancreatic cancer.
    Zhu H; Gao W; Li X; Yu L; Luo D; Liu Y; Yu X
    Pancreatology; 2021 Apr; 21(3):589-598. PubMed ID: 33579599
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Small non-coding RNAs and pancreatic ductal adenocarcinoma: Linking diagnosis, pathogenesis, drug resistance, and therapeutic potential.
    Fuller RN; Morcos A; Bustillos JG; Molina DC; Wall NR
    Biochim Biophys Acta Rev Cancer; 2024 Sep; 1879(5):189153. PubMed ID: 38986720
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer.
    Nagathihalli NS; Castellanos JA; Shi C; Beesetty Y; Reyzer ML; Caprioli R; Chen X; Walsh AJ; Skala MC; Moses HL; Merchant NB
    Gastroenterology; 2015 Dec; 149(7):1932-1943.e9. PubMed ID: 26255562
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Microbiome and pancreatic cancer: time to think about chemotherapy.
    de Castilhos J; Tillmanns K; Blessing J; Laraño A; Borisov V; Stein-Thoeringer CK
    Gut Microbes; 2024; 16(1):2374596. PubMed ID: 39024520
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Curcumin sensitizes pancreatic cancer cells to gemcitabine by attenuating PRC2 subunit EZH2, and the lncRNA PVT1 expression.
    Yoshida K; Toden S; Ravindranathan P; Han H; Goel A
    Carcinogenesis; 2017 Oct; 38(10):1036-1046. PubMed ID: 29048549
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TET1 downregulates epithelial-mesenchymal transition and chemoresistance in PDAC by demethylating CHL1 to inhibit the Hedgehog signaling pathway.
    Li H; Jiang W; Liu XN; Yuan LY; Li TJ; Li S; Xu SS; Zhang WH; Gao HL; Han X; Wang WQ; Wu CT; Yu XJ; Xu HX; Liu L
    Oncogene; 2020 Sep; 39(36):5825-5838. PubMed ID: 32753651
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chemoresistance in Pancreatic Cancer.
    Zeng S; Pöttler M; Lan B; Grützmann R; Pilarsky C; Yang H
    Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31514451
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Next-generation therapies for pancreatic cancer.
    Buckley CW; O'Reilly EM
    Expert Rev Gastroenterol Hepatol; 2024; 18(1-3):55-72. PubMed ID: 38415709
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chemotherapy-Derived Inflammatory Responses Accelerate the Formation of Immunosuppressive Myeloid Cells in the Tissue Microenvironment of Human Pancreatic Cancer.
    Takeuchi S; Baghdadi M; Tsuchikawa T; Wada H; Nakamura T; Abe H; Nakanishi S; Usui Y; Higuchi K; Takahashi M; Inoko K; Sato S; Takano H; Shichinohe T; Seino K; Hirano S
    Cancer Res; 2015 Jul; 75(13):2629-40. PubMed ID: 25952647
    [TBL] [Abstract][Full Text] [Related]  

  • 30. GATA6 Expression Distinguishes Classical and Basal-like Subtypes in Advanced Pancreatic Cancer.
    O'Kane GM; Grünwald BT; Jang GH; Masoomian M; Picardo S; Grant RC; Denroche RE; Zhang A; Wang Y; Lam B; Krzyzanowski PM; Lungu IM; Bartlett JMS; Peralta M; Vyas F; Khokha R; Biagi J; Chadwick D; Ramotar S; Hutchinson S; Dodd A; Wilson JM; Notta F; Zogopoulos G; Gallinger S; Knox JJ; Fischer SE
    Clin Cancer Res; 2020 Sep; 26(18):4901-4910. PubMed ID: 32156747
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel agents for pancreatic ductal adenocarcinoma: emerging therapeutics and future directions.
    Zhang Y; Yang C; Cheng H; Fan Z; Huang Q; Lu Y; Fan K; Luo G; Jin K; Wang Z; Liu C; Yu X
    J Hematol Oncol; 2018 Jan; 11(1):14. PubMed ID: 29386069
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Integrinβ1 modulates tumour resistance to gemcitabine and serves as an independent prognostic factor in pancreatic adenocarcinomas.
    Yang D; Shi J; Fu H; Wei Z; Xu J; Hu Z; Zhang Y; Yan R; Cai Q
    Tumour Biol; 2016 Sep; 37(9):12315-12327. PubMed ID: 27289231
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A novel multidrug-resistant cell line from a Chinese patient with pancreatic ductal adenocarcinoma.
    Tang H; Miao X; Yu C; Chai C; Su Y; Li L; Yi J; Ye Z; Miao L; Wang Z; Zhang H; Xu H; Zhou W
    Sci Rep; 2024 Apr; 14(1):9259. PubMed ID: 38649719
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A tunable delivery platform to provide local chemotherapy for pancreatic ductal adenocarcinoma.
    Indolfi L; Ligorio M; Ting DT; Xega K; Tzafriri AR; Bersani F; Aceto N; Thapar V; Fuchs BC; Deshpande V; Baker AB; Ferrone CR; Haber DA; Langer R; Clark JW; Edelman ER
    Biomaterials; 2016 Jul; 93():71-82. PubMed ID: 27082874
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Extracellular vesicle-packaged circBIRC6 from cancer-associated fibroblasts induce platinum resistance via SUMOylation modulation in pancreatic cancer.
    Zheng S; Tian Q; Yuan Y; Sun S; Li T; Xia R; He R; Luo Y; Lin Q; Fu Z; Zhou Y; Chen R; Hu C
    J Exp Clin Cancer Res; 2023 Nov; 42(1):324. PubMed ID: 38012734
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MiRNA-3662 reverses the gemcitabine resistance in pancreatic cancer through regulating the tumor metabolism.
    Liu A; Zhou Y; Zhao T; Tang X; Zhou B; Xu J
    Cancer Chemother Pharmacol; 2021 Aug; 88(2):343-357. PubMed ID: 33993382
    [TBL] [Abstract][Full Text] [Related]  

  • 37. RETSAT associates with DDX39B to promote fork restarting and resistance to gemcitabine based chemotherapy in pancreatic ductal adenocarcinoma.
    Tu Q; Liu X; Yao X; Li R; Liu G; Jiang H; Li K; Chen Q; Huang X; Chang Q; Xu G; Zhu H; Shi P; Zhao B
    J Exp Clin Cancer Res; 2022 Sep; 41(1):274. PubMed ID: 36109793
    [TBL] [Abstract][Full Text] [Related]  

  • 38. LLGL1 Regulates Gemcitabine Resistance by Modulating the ERK-SP1-OSMR Pathway in Pancreatic Ductal Adenocarcinoma.
    Zhu YX; Li CH; Li G; Feng H; Xia T; Wong CH; Fung FKC; Tong JH; To KF; Chen R; Chen Y
    Cell Mol Gastroenterol Hepatol; 2020; 10(4):811-828. PubMed ID: 32615164
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gemcitabine: A Review of Chemoresistance in Pancreatic Cancer.
    Sarvepalli D; Rashid MU; Rahman AU; Ullah W; Hussain I; Hasan B; Jehanzeb S; Khan AK; Jain AG; Khetpal N; Ahmad S
    Crit Rev Oncog; 2019; 24(2):199-212. PubMed ID: 31679214
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Notch signaling activated by replication stress-induced expression of midkine drives epithelial-mesenchymal transition and chemoresistance in pancreatic cancer.
    Güngör C; Zander H; Effenberger KE; Vashist YK; Kalinina T; Izbicki JR; Yekebas E; Bockhorn M
    Cancer Res; 2011 Jul; 71(14):5009-19. PubMed ID: 21632553
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.